MTIC (Synonyms: NSC 407347) |
Catalog No.GC44251 |
MTIC is a DNA alkylating agent, an active metabolite of dacarbazine, and an active degradation product of temozolomide.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 3413-72-7
Sample solution is provided at 25 µL, 10mM.
MTIC is a DNA alkylating agent, an active metabolite of dacarbazine, and an active degradation product of temozolomide.[1],[2],[3] MTIC is cytotoxic to L-cells and decreases thymidine and uridine uptake by 55 and 65%, respectively, when used at a concentration of 1 mM.[2] It is also cytotoxic to TLX5 murine lymphoma cells in a concentration-dependent manner.[3] In vivo, MTIC induces formation of mammary adenofibromas in rats when administered at a cumulative dose of 890 mg per animal over 14 weeks.[4]
Reference:
[1]. Nagasawa, H.T., Shirota, F.N., and Mizuno, N.S. The mechanism of alkylation of DNA by 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MIC), a metabolite of DIC (NSC-45388). Non-involvement of diazomethane. Chem. Biol. Interact. 8(6), 403-413 (1974).
[2]. Beal, D.D., Skibba, J.L., Whitnable, K.K., et al. Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide and its metabolites on Novikoff hepatoma cells. Cancer Res. 36(8), 2827-2831 (1976).
[3]. Tsang, L.L.H., Quarterman, C.P., Gescher, A., et al. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother. Pharmacol. 27(5), 342-346 (1991).
[4]. Beal, D.D., Skibba, J.L., Croft, W.A., et al. Carcinogenicity of the antineoplastic agent, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, and its metabolites in rats. J. Natl. Cancer Inst. 54(4), 951-957 (1975).
Average Rating: 5
(Based on Reviews and 29 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *